TMCnet News

Hepatitis B Virus (HBV) Therapeutics Report 2016 - 5EU Drug Forecast and Market Analysis to 2024 - Research and Markets
[June 22, 2016]

Hepatitis B Virus (HBV) Therapeutics Report 2016 - 5EU Drug Forecast and Market Analysis to 2024 - Research and Markets


Research and Markets has announced the addition of the "Hepatitis B Virus (HBV) Therapeutics - 5EU Drug Forecast and Market Analysis to 2024" report to their offering.

The chronic hepatitis B therapeutics market in the 5EU was valued at $532.1m in 2014. The anticipated arrival of novel branded therapies will be the strongest market driver in the 5EU during the forecast period. These therapies include Gilead's TAF, a novel NA, along with three adjunct therapies, Arrowhead's ARC-520, Gilead's GS-9620, and Gilead's GS-4774. GlobalData projects these four products will receive licensure in the 5EU in 2017, 2021, 2021, and 2023, respectively.

Scope

- Overview of HBV, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

- Detailed information on the key drugs in 5EU, including product description, safety and efficacy profiles as well as a SWOT analysis.

- Sales forecast for thetop drugs in 5EU from 2014-2024.



- Analysis of the impact of key events as well the drivers and restraints affecting the 5EU HBV market.

Key Topics Covered:


1. Tables & Figures

2 Introduction

2.1 Catalyst

2.2 Related Reports

2.3 Upcoming Related Reports

3 Disease Overview

3.1 Overview

3.2 Etiology and Pathophysiology

3.3 Symptoms

3.4 Prognosis (News - Alert)

3.5 Quality of Life

4 Disease Management

4.1 Diagnosis and Treatment Overview

4.2 5EU

5 Competitive Assessment

5.1 Overview

5.2 Product Profiles - Major Brands

5.3 Other Therapeutics

6 Unmet Need and Opportunity

6.1 Overview

6.2 Improvements in Long-Term Clinical Outcomes

6.3 Enhanced Public Awareness and Screening Initiatives to Boost Diagnosis Rates

6.4 Increased Access to Treatment

6.5 Drugs That Effectively Target (News - Alert) and Suppress HBV cccDNA

6.6 Safe and Efficacious Therapies for Difficult-to-Treat Patients

6.7 Overcome Unique Barriers Posed by China's Healthcare System

7 Pipeline Assessment

7.1 Overview

7.2 Clinical Trial Mapping

7.3 Promising Drugs in Clinical Development

7.4 Other Drugs in Development

8 Market Outlook

8.1 5EU

9 Appendix

For more information visit http://www.researchandmarkets.com/research/h8gk3x/hepatitis_b_virus.


[ Back To TMCnet.com's Homepage ]